$MNKD
MANNKIND CORP

2017 Q3 Form 10-Q Financial Statement

#000156459017022243 Filed on November 07, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3 2015 Q4
Revenue $2.043M $162.4M $0.00
YoY Change -98.74%
Cost Of Revenue $4.575M $4.331M $51.80M
YoY Change 5.63% -46.63%
Gross Profit -$2.532M $158.0M -$51.80M
YoY Change -101.6% -2047.3%
Gross Profit Margin -123.94% 97.33%
Selling, General & Admin $17.73M $13.14M $8.300M
YoY Change 34.94% 13.75% -33.6%
% of Gross Profit 8.31%
Research & Development $4.400M $3.917M $6.200M
YoY Change 12.33% -38.23% -64.77%
% of Gross Profit 2.48%
Depreciation & Amortization $454.0K $597.0K $3.190M
YoY Change -23.95% -81.14% 5.98%
% of Gross Profit 0.38%
Operating Expenses $17.73M $17.05M $14.50M
YoY Change 3.95% -34.42% -51.83%
Operating Profit -$28.18M $118.2M -$66.30M
YoY Change -123.83% -554.67%
Interest Expense -$8.400M $8.300M -$4.100M
YoY Change -201.2% -269.39% -35.94%
% of Operating Profit 7.02%
Other Income/Expense, Net -$4.707M $8.291M -$100.0K
YoY Change -156.77% 12274.63%
Pretax Income -$32.89M $126.5M -$277.0M
YoY Change -125.99% -497.15% 660.99%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$32.89M $126.5M -$277.0M
YoY Change -125.99% -497.15% 660.23%
Net Earnings / Revenue -1609.69% 77.93%
Basic Earnings Per Share -$0.31 $1.32
Diluted Earnings Per Share -$0.31 $1.31 -$3.302M
COMMON SHARES
Basic Shares Outstanding 104.7M 95.63M 409.5M shares
Diluted Shares Outstanding 104.7M 96.55M

Balance Sheet

Concept 2017 Q3 2016 Q3 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.10M $35.50M $59.10M
YoY Change -43.38% 7.9% -51.08%
Cash & Equivalents $20.09M $35.53M $59.07M
Short-Term Investments
Other Short-Term Assets $3.600M $4.800M $17.50M
YoY Change -25.0% -63.64% -13.37%
Inventory $3.129M $5.124M $0.00
Prepaid Expenses $15.00M
Receivables $1.804M $3.137M $23.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $28.63M $48.60M $76.65M
YoY Change -41.1% -31.77% -61.89%
LONG-TERM ASSETS
Property, Plant & Equipment $27.37M $46.83M $48.75M
YoY Change -41.54% -75.54% -74.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $480.0K $702.0K $1.009M
YoY Change -31.62% -61.66% 18.99%
Total Long-Term Assets $27.85M $47.53M $49.76M
YoY Change -41.39% -77.02% -74.26%
TOTAL ASSETS
Total Short-Term Assets $28.63M $48.60M $76.65M
Total Long-Term Assets $27.85M $47.53M $49.76M
Total Assets $56.48M $96.13M $126.4M
YoY Change -41.24% -65.42% -67.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.283M $5.093M $15.60M
YoY Change 3.73% 14.6% 110.97%
Accrued Expenses $12.49M $14.16M $7.929M
YoY Change -11.8% 0.59% -69.74%
Deferred Revenue
YoY Change
Short-Term Debt $57.90M $70.90M $74.60M
YoY Change -18.34% -4.45% 2.19%
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $91.50M $105.8M $268.3M
YoY Change -13.54% -60.41% -33.48%
LONG-TERM LIABILITIES
Long-Term Debt $107.3M $148.4M $139.5M
YoY Change -27.7% 22.85% 165.21%
Other Long-Term Liabilities $108.7M $17.40M $15.23M
YoY Change 524.82% 20.02% 23.77%
Total Long-Term Liabilities $216.0M $17.40M $15.23M
YoY Change 1141.59% 20.02% 23.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $91.50M $105.8M $268.3M
Total Long-Term Liabilities $216.0M $17.40M $15.23M
Total Liabilities $307.5M $334.8M $476.7M
YoY Change -8.16% -16.83% 1.82%
SHAREHOLDERS EQUITY
Retained Earnings -$2.792B -$2.863B
YoY Change 7.94% 14.77%
Common Stock $2.553B $2.513B
YoY Change 3.71% 3.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$251.0M -$238.7M -$350.3M
YoY Change
Total Liabilities & Shareholders Equity $56.50M $96.13M $126.4M
YoY Change -41.23% -65.42% -67.95%

Cashflow Statement

Concept 2017 Q3 2016 Q3 2015 Q4
OPERATING ACTIVITIES
Net Income -$32.89M $126.5M -$277.0M
YoY Change -125.99% -497.15% 660.23%
Depreciation, Depletion And Amortization $454.0K $597.0K $3.190M
YoY Change -23.95% -81.14% 5.98%
Cash From Operating Activities -$23.27M -$23.07M -$22.55M
YoY Change 0.87% 15.99% -36.91%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$320.0K
YoY Change -100.0% -93.56%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 -$310.0K
YoY Change -100.0% -97.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -20.00K -5.130M 49.01M
YoY Change -99.61% -90.36% -3034.73%
NET CHANGE
Cash From Operating Activities -23.27M -23.07M -22.55M
Cash From Investing Activities 0.000 0.000 -310.0K
Cash From Financing Activities -20.00K -5.130M 49.01M
Net Change In Cash -23.29M -28.20M 26.15M
YoY Change -17.41% -62.02% -150.65%
FREE CASH FLOW
Cash From Operating Activities -$23.27M -$23.07M -$22.55M
Capital Expenditures $0.00 $0.00 -$320.0K
Free Cash Flow -$23.27M -$23.07M -$22.23M
YoY Change 0.87% 23.63% -27.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1804000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
302000
CY2016Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
30557000
CY2017Q3 us-gaap Inventory Net
InventoryNet
3129000
CY2016Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
16730000
CY2016Q4 us-gaap Other Deferred Costs Net
OtherDeferredCostsNet
309000
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3021000
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
7381000
CY2017Q3 mnkd Milestone Rights Liability And Other Liabilities Noncurrent
MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent
7202000
CY2016Q4 mnkd Milestone Rights Liability And Other Liabilities Noncurrent
MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent
8845000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84545000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
71689000
CY2017Q3 us-gaap Other Deferred Costs Net
OtherDeferredCostsNet
543000
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3061000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22895000
CY2016Q4 us-gaap Inventory Net
InventoryNet
2331000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
28629000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27374000
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
480000
CY2017Q3 us-gaap Assets
Assets
56483000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5283000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12492000
CY2017Q3 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
57942000
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
117147107
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20092000
us-gaap Costs And Expenses
CostsAndExpenses
86567000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28179000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
44125000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000
CY2016Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4166000
us-gaap Investment Income Interest
InvestmentIncomeInterest
178000
CY2017Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
2310000
us-gaap Operating Income Loss
OperatingIncomeLoss
79093000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79352000
us-gaap Costs And Expenses
CostsAndExpenses
83261000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
118229000
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
65000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-830000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000
us-gaap Share Based Compensation
ShareBasedCompensation
4130000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-247000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1502000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7403000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13357000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31595000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-12077000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
203000
CY2017Q3 mnkd Gain Loss On Purchase Commitments
GainLossOnPurchaseCommitments
215000
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1981000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
573000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
4726000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
573000
CY2017Q3 mnkd Net Revenue From Collaboration
NetRevenueFromCollaboration
62000
CY2016Q3 mnkd Net Revenue From Collaboration
NetRevenueFromCollaboration
161781000
mnkd Net Revenue From Collaboration
NetRevenueFromCollaboration
187000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
2302000
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
2043000
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
162354000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
12912000
CY2016Q3 mnkd Product Costs From Collaboration
ProductCostsFromCollaboration
22742000
mnkd Product Costs From Collaboration
ProductCostsFromCollaboration
22742000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
695000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-3035000
CY2016Q3 mnkd Gain Loss On Purchase Commitments
GainLossOnPurchaseCommitments
1075000
mnkd Gain Loss On Purchase Commitments
GainLossOnPurchaseCommitments
215000
mnkd Gain Loss On Purchase Commitments
GainLossOnPurchaseCommitments
1075000
CY2017Q3 mnkd Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-1289000
CY2016Q3 mnkd Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
13185000
mnkd Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
5488000
mnkd Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
7879000
us-gaap Investment Income Interest
InvestmentIncomeInterest
70000
us-gaap Interest Expense Debt
InterestExpenseDebt
7438000
us-gaap Interest Expense Debt
InterestExpenseDebt
12567000
CY2017Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1173000
CY2016Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
729000
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
2608000
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
2172000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4707000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5197000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-613000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8291000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-84549000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
71690000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-32886000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
126520000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32886000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
126520000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Income Loss
NetIncomeLoss
-84549000
us-gaap Net Income Loss
NetIncomeLoss
71690000
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104703000
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95627000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100136000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90838000
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104703000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96549000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100136000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90873000
CY2017Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32885000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
126520000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2707000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3097000
us-gaap Share Based Compensation
ShareBasedCompensation
3763000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
24000
us-gaap Paid In Kind Interest
PaidInKindInterest
4125000
mnkd Interest On Note Payable To Principal Stockholder
InterestOnNotePayableToPrincipalStockholder
2608000
mnkd Interest On Note Payable To Principal Stockholder
InterestOnNotePayableToPrincipalStockholder
2172000
mnkd Warrant Issuance Costs
WarrantIssuanceCosts
653000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-717000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3114000
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-30557000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
798000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5124000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-13539000
mnkd Increase Decrease In Other Deferred Charges
IncreaseDecreaseInOtherDeferredCharges
234000
mnkd Increase Decrease In Other Deferred Charges
IncreaseDecreaseInOtherDeferredCharges
279000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1303000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
516000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-166000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-307000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2099000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10288000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2889000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6575000
mnkd Increase Decrease In Deferred Collaborative Revenue
IncreaseDecreaseInDeferredCollaborativeRevenue
-17503000
us-gaap Increase Decrease In Customer Advances And Deposits
IncreaseDecreaseInCustomerAdvancesAndDeposits
-187000
us-gaap Increase Decrease In Customer Advances And Deposits
IncreaseDecreaseInCustomerAdvancesAndDeposits
-135056000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-398000
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
93000000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2014000
mnkd Increase Decrease In Purchase Commitment Loss
IncreaseDecreaseInPurchaseCommitmentLoss
-648000
mnkd Increase Decrease In Purchase Commitment Loss
IncreaseDecreaseInPurchaseCommitmentLoss
3442000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
16651000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
24000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-65338000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1144000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-34797000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
17000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
16675000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1127000
mnkd Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
772000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
50000000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
2690000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
4000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
5000000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
19429000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
110000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
161000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15319000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
42921000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2803000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-23544000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59074000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35530000
us-gaap Interest Paid Net
InterestPaidNet
6373000
us-gaap Interest Paid Net
InterestPaidNet
7198000
us-gaap Stock Issued1
StockIssued1
11000000
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
10716000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
1893000
us-gaap Loans Assumed1
LoansAssumed1
4713000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reclassifications <font style="font-style:normal;">&#8212; Certain amounts from previous periods have been reclassified to conform to the 2017 presentation. Specifically, the Company reclassified property and equipment impairment, loss on foreign currency translation and gain on purchase commitments from the previously reported classification of cost of goods sold to separate line items on the condensed consolidated statement of operations. In the condensed consolidated statement of cash flows, the Company reclassified the gain on purchase commitments from the change in recognized loss on purchase commitments. </font></p></div>
us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition &#8211; Net Revenue &#8211; Commercial Product Sales &#8211;<font style="font-style:normal;"> The Company currently sells Afrezza through two channels: wholesale distributors and specialty pharmacies as further described below. The Company provides the right of return for unopened product for a period beginning six months prior to and ending twelve months after its expiration date. This right of return is provided to (1) the Company&#8217;s wholesale distributors and, through them, to its retail pharmacy customers, and (2) to its specialty pharmacies.&nbsp;&nbsp;Once the product has been prescribed and dispensed to the patient, any right of return ceases to exist. &nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales of Afrezza through Wholesale Distributors<font style="font-style:normal;"> - Between July&#160;1, 2016 and December&#160;15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (&#8220;ICS&#8221;) and title and risk of loss transferred to ICS upon shipment. After December&#160;15, 2016, ICS became a third party logistics provider and stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as &#8220;customers&#8221;.</font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the Company&#8217;s limited sales history for Afrezza, through wholesale distributors, the Company cannot currently reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments through wholesale distributors until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. Deferred revenue is presented net of deferred product sales discounts which are further described in <font style="font-style:italic;">Gross-to-net Adjustments</font> below. The Company recognizes revenue for wholesale distributors based on Afrezza patient prescriptions dispensed as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable, including data related to inventory movements within the channel and ongoing prescription demand. </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales of Afrezza through Specialty Pharmacies<font style="font-style:normal;"> - During the three months ended September 30, 2017, the Company began selling Afrezza to a network of specialty pharmacies. Specialty pharmacies generally purchase product on demand.&nbsp;&nbsp;Title and risk of loss passes to the specialty pharmacies at shipment and our estimated returns are minimal.&nbsp;&nbsp;Therefore, the Company recognizes revenue for sales through specialty pharmacies at the time the product is shipped to the specialty pharmacies, net of </font>Gross-to-net Adjustments<font style="font-style:normal;"> as described below. For the three and nine months ended September 30, 2017 the amount of revenue recognized from sales to specialty pharmacies was de minimis.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenue from commercial product sales consisted of $2.0 million and $4.7 million of net sales of Afrezza, for the three and nine months ended September 30, 2017, respectively. As of September 30, 2017 and December&#160;31, 2016, the ending balances for net deferred revenue, were $3.0&#160;million and $3.4&#160;million, on the Company&#8217;s condensed consolidated balance sheets which are presented net of $1.1 million and $0.8&#160;million in gross-to-net revenue adjustments, respectively. The December&#160;31, 2016 deferred revenue balance includes $1.7 million of bulk insulin sales which is described more fully under the heading <font style="font-style:italic;">Revenue Recognition &#8211; Revenue &#8211; Other</font> below. For the three and nine months ended September 30, 2017, shipments to three wholesale distributors represented 92% of total shipments.</p></div>
us-gaap Revenue Recognition Discounts
RevenueRecognitionDiscounts
<div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Prompt Pay Discounts &#8211;<font style="font-style:normal;"> The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable and deferred revenue by the prompt pay discount amount (at the time of shipment to the wholesale distributor). The Company recognizes cash discounts as a reduction of revenue in the same period the related revenue is recognized. </font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Rebates and Chargebacks &#8211;<font style="font-style:normal;"> The Company participates in federal and state government-managed Medicare and Medicaid programs and, as such, is required to provide rebates under these programs. Chargebacks are discounts that occur when contracted customers purchase directly from an intermediary wholesale purchaser. Contracted customers, which currently consist primarily of Federal government entities purchasing off the Federal Supply Schedule, generally purchase the product at its contracted price, plus a mark-up from the wholesaler or specialty pharmacy. The wholesaler/specialty pharmacy, in-turn, charges back to the Company the difference between the price initially paid by the wholesaler/specialty pharmacy and the contracted price paid to the wholesaler/specialty pharmacy by the customer. </font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for these rebates and chargebacks by establishing an accrual based on contractual discount rates, expected utilization under each contract and an estimate of the amount of inventory in the distribution channel that will become subject to such rebates and chargebacks based on historical payor data provided by a third-party vendor along with additional data including forecasted participation rates. From that data, as well as input received from the commercial team, an estimated participation rate for each program is determined and applied at the rate for those sales. Any new information regarding changes in the programs&#8217; regulations and guidelines or any changes in the Company&#8217;s government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between the date the product is sold into the channel and the date such rebates may be paid can be up to approximately six to nine months. As such, continuous monitoring of these estimates will be performed on a periodic basis, and if necessary, adjusted to reflect new facts and circumstances. Rebates and chargebacks are recognized as a reduction of gross revenue in the period the related revenue is recognized. </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Rebates and Discounts &#8211;<font style="font-style:normal;"> The Company has entered into agreements with certain third-party payors and with pharmacy benefit managers that act as an intermediary with certain third-party payors in the fulfillment of prescriptions. Under these agreements, the Company has agreed to provide certain contracted discounts to ease access to reimbursement for Afrezza patients including, but not limited to, the removal of prior authorization or step edit requirements or modifying the reimbursement tier under the payor&#8217;s formulary. The Company accounts for these charges by establishing an accrual based on the contracted discount rates and, with input received from management, estimated participation rates. </font></p></div>
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Costs from Commercial Product Sales <font style="font-style:normal;">&#8212; Deferred costs from commercial product sales represents the cost of product (including labor, overhead and shipping costs to the third party logistics provider) shipped to wholesale distributors, but not dispensed by retail pharmacies to patients. If the Company estimates that inventory that has been shipped to wholesale distributors will be returned for credit because there is a risk of product expiry, deferred costs of commercial product sales is reduced and cost of goods sold is increased for the cost of such inventory. </font></p></div>
us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition &#8211; Net Revenue &#8211; Collaborations &#8211;<font style="font-style:normal;"> The Company enters into collaborations under which the Company must perform certain obligations and receives periodic payments. The Company evaluates the collaborations under the multiple element revenue recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit. The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company&#8217;s collaborations are described more fully in Note 7 &#8212; Collaboration Arrangements. </font></p></div>
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2017Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
140000000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
700000000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
CY2017Q3 mnkd Number Of Wholesale Distributors
NumberOfWholesaleDistributors
3
mnkd Number Of Wholesale Distributors
NumberOfWholesaleDistributors
3
CY2017Q3 mnkd Percentage Of Product Shipments To Wholesale Distributors
PercentageOfProductShipmentsToWholesaleDistributors
0.92
mnkd Percentage Of Product Shipments To Wholesale Distributors
PercentageOfProductShipmentsToWholesaleDistributors
0.92
CY2016 mnkd Deferred Revenue From Sale Of Raw Insulin
DeferredRevenueFromSaleOfRawInsulin
1700000
CY2017Q3 mnkd Cash Discount Percent
CashDiscountPercent
0.02
mnkd Deferred Revenue From Sale Of Raw Insulin
DeferredRevenueFromSaleOfRawInsulin
0
CY2017Q3 mnkd Number Of Customers Accounted For Gross Accounts Receivable
NumberOfCustomersAccountedForGrossAccountsReceivable
3
CY2016Q4 mnkd Number Of Customers Accounted For Gross Accounts Receivable
NumberOfCustomersAccountedForGrossAccountsReceivable
3
CY2017Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2017Q3 mnkd Percentage Of Accounts Receivable From Major Customers
PercentageOfAccountsReceivableFromMajorCustomers
0.92
CY2016Q4 mnkd Percentage Of Accounts Receivable From Major Customers
PercentageOfAccountsReceivableFromMajorCustomers
0.95
mnkd Loss On Purchase Commitments Number Of Contracts Recognized
LossOnPurchaseCommitmentsNumberOfContractsRecognized
0
CY2016 mnkd Loss On Purchase Commitments Number Of Contracts Recognized
LossOnPurchaseCommitmentsNumberOfContractsRecognized
0
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
20500000
CY2017Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
103400000
CY2017Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
345000
CY2016Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
123200000
CY2017Q3 mnkd Purchase Obligation Due In Seventh Year
PurchaseObligationDueInSeventhYear
19400000
mnkd Long Term Purchase Commitment Expiration Date
LongTermPurchaseCommitmentExpirationDate
2023-12-31
mnkd Longterm Purchase Commitment Renewal Time Period
LongtermPurchaseCommitmentRenewalTimePeriod
P2Y
CY2017Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2329000
CY2016Q2 mnkd Warrants Fair Value
WarrantsFairValue
12800000
CY2017Q3 mnkd Current Portion Of Milestone Right Liability
CurrentPortionOfMilestoneRightLiability
1643000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1063000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
875000
mnkd Fair Value Of Liability Percentage Decrease
FairValueOfLiabilityPercentageDecrease
0.07
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
11600000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1247000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1502000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3763000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4130000
CY2017Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
34720
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.06
CY2017Q3 mnkd Number Of Equal Tranches
NumberOfEqualTranches
4
CY2017Q3 mnkd Purchase Obligation Due In Remainder Of Fiscal Year
PurchaseObligationDueInRemainderOfFiscalYear
2700000
CY2017Q3 mnkd Customer Discounts And Allowances
CustomerDiscountsAndAllowances
1239000
CY2016Q4 mnkd Customer Discounts And Allowances
CustomerDiscountsAndAllowances
754000
CY2017Q3 mnkd Sales And Marketing Related Expenses Accrued
SalesAndMarketingRelatedExpensesAccrued
797000
CY2016Q4 mnkd Sales And Marketing Related Expenses Accrued
SalesAndMarketingRelatedExpensesAccrued
144000
CY2017Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
362000
CY2016Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1376000
CY2017Q3 us-gaap Interest Payable Current
InterestPayableCurrent
234000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
619000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
722000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
355000
CY2017Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
8900000
CY2017Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
11600000
CY2017Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
15500000
CY2017Q3 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
15500000
CY2017Q3 mnkd Purchase Obligation Due In Sixth Year
PurchaseObligationDueInSixthYear
19400000
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
10000000
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
30000000
CY2017Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
18400000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2120000
CY2017Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
455000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
211000
CY2017Q3 us-gaap Production Related Impairments Or Charges
ProductionRelatedImpairmentsOrCharges
300000
us-gaap Production Related Impairments Or Charges
ProductionRelatedImpairmentsOrCharges
1800000
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
128076000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
128502000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100702000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
99575000
CY2017Q3 us-gaap Depreciation
Depreciation
454000
CY2016Q3 us-gaap Depreciation
Depreciation
597000
us-gaap Depreciation
Depreciation
1350000
us-gaap Depreciation
Depreciation
1775000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6432000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3814000
CY2016Q2 us-gaap Stock Issued1
StockIssued1
44700000
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.50
CY2017Q3 mnkd Number Of Warrant Holders
NumberOfWarrantHolders
4
CY2017Q3 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
1900000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
41000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
457000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
512000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
528000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
544000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
560000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2642000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
1014000
CY2016Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
921000
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
36000
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9320830
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15617115
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9320830
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16431676

Files In Submission

Name View Source Status
0001564590-17-022243-index-headers.html Edgar Link pending
0001564590-17-022243-index.html Edgar Link pending
0001564590-17-022243.txt Edgar Link pending
0001564590-17-022243-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mnkd-10q_20170930.htm Edgar Link pending
mnkd-20170930.xml Edgar Link completed
mnkd-20170930.xsd Edgar Link pending
mnkd-20170930_cal.xml Edgar Link unprocessable
mnkd-20170930_def.xml Edgar Link unprocessable
mnkd-20170930_lab.xml Edgar Link unprocessable
mnkd-20170930_pre.xml Edgar Link unprocessable
mnkd-ex311_9.htm Edgar Link pending
mnkd-ex312_8.htm Edgar Link pending
mnkd-ex321_6.htm Edgar Link pending
mnkd-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending